


#### **QUARTERLY TESTING STATISTICS**

Q2 2024 APRIL 1 - JUNE 30, 2024




#### TOTAL SAMPLE COLLECTION SESSIONS IN Q2 2024





### NUMBER OF ADVERSE ANALYTICAL FINDINGS (AAFs) BY MATRIX



### 0.51%


of all sample collection sessions resulted in AAFs

|    | TOTAL SAMPLE<br>COLLECTION<br>SESSIONS | TOTAL<br>AAFs |
|----|--|---------------|
| AR | 537                                    | 3             |
| ΑZ | 368                                    | 1             |
| CA | 3,113                                  | 10            |
| DE | 426                                    | 6             |
| FL | 2,084                                  | 9             |
| IA | 498                                    | 5             |
| IL | 892                                    | 6             |
| IN | 844                                    | 1             |
| KY | 2,388                                  | 16            |
| MD | 1,251                                  | 5             |
| MN | 403                                    | 0             |
| NJ | 559                                    | 2             |
| NM | 173                                    | 0             |
| NY | 2,277                                  | 7             |
| ОН | 1,800                                  | 12            |
| ОК | 303                                    | 3             |
| PA | 1,736                                  | 9             |
| VA | 2                                      | 1             |
| WA | 409                                    | 6             |
|    | 20,063                                 | 102           |
|    | Total                                  | Total         |



| Banned                               |    | Controlled<br>Method | k | Controlled<br>A | Controlled<br>B |    | Controlled<br>C           |    |
|--------------------------------------|----|----------------------|---|-----------------|-----------------|----|---------------------------|----|
| Clenbuterol                          | 10 | TCO2                 | 4 |                 | Acepromazine    | 11 | Acetaminophen             | 3  |
| D-Methamphetamine                    | 4  |                      |   |                 | Albuterol       | 1  | Aminocaproic Acid         | 2  |
| Formestane/<br>4-Hydroxytestosterone | 1  |                      |   |                 | Cannabidiol 4   |    | Betamethasone             | 3  |
| Metformin                            | 6  |                      |   |                 | Capsaicin 3     |    | Cetirizine                | 2  |
| Oxycodone/<br>Oxymorphone            | -  |                      |   |                 | Gabapentin      | 1  | Dantrolene                | 6  |
|                                      |    |                      |   |                 | Lidocaine       | 1  | Dexamethasone             | 12 |
|                                      |    |                      |   |                 | Xylazine        | 1  | Dimethyl Sulfoxide (DMSO) | 1  |
|                                      |    |                      |   |                 |                 |    | Flunixin                  | 2  |
|                                      |    |                      |   |                 |                 |    | Glycopyrrolate            | 1  |
|                                      |    |                      |   |                 |                 |    | Methocarbamol             | 5  |
|                                      |    |                      |   |                 |                 |    | Omeprazole Sulfide        | 4  |
|                                      |    |                      |   |                 |                 |    | Phenylbutazone            | 12 |
|                                      |    |                      |   |                 |                 |    | Triamcinolone Acetonide   | 1  |
| 22                                   |    | 4                    |   | 0               | 22              |    | 54                        |    |
| 102 Adverse Analytical Findings      |    |                      |   |                 |                 |    |                           |    |

PERCENTAGE OF AAFs BY BANNED OR CONTROLLED STATUS



#### AVERAGE TIME FOR TEST RESULTS TO BE REPORTED TO HIWU

7.6
business days

**Post-Race** 

**Testing** 

Vets' List & Clearance Testing

4.4

business days B Sample Testing

**13**.6

business days



### EQUINE ANTI-DOPING (EAD) & EQUINE CONTROLLED MEDICATION (ECM) NOTICES & CHARGES FILED BY STATE\*

\* This chart does not reflect IAI Cases

|       |                         |                         | •                       |                         |
|-------|-------------------------|-------------------------|-------------------------|-------------------------|
| State | EAD<br>Notices<br>Filed | EAD<br>Charges<br>Filed | ECM<br>Notices<br>Filed | ECM<br>Charges<br>Filed |
| AR    | 1                       | 0                       | 2                       | 2                       |
| AZ    | 0                       | 0                       | 1                       | 1                       |
| CA    | 1                       | 1                       | 11                      | 11                      |
| СО    | 0                       | 0                       | 0                       | 0                       |
| DE    | 3                       | 2                       | 3                       | 3                       |
| FL    | 4                       | 3                       | 6                       | 6                       |
| IA    | 0                       | 0                       | 4                       | 4                       |
| IL    | 3                       | 2                       | 4                       | 4                       |
| IN    | 0                       | 0                       | 1                       | 1                       |
| KY    | 2                       | 2                       | 13                      | 13                      |
| MD    | 0                       | 0                       | 5                       | 5                       |
| MN    | 0                       | 0                       | 0                       | 0                       |
| ИJ    | 0                       | 0                       | 2                       | 2                       |
| NM    | 0                       | 0                       | 0                       | 0                       |
| NY    | 0                       | 0                       | 8                       | 8                       |
| ОН    | 6                       | 6                       | 4                       | 4                       |
| ок    | 1                       | 0                       | 2                       | 2                       |
| PA    | 1                       | 1                       | 8                       | 5                       |
| VA    | 0                       | 0                       | 1                       | 1                       |
| WA    | 1                       | 1                       | 5                       | 5                       |
| TOTAL | 23                      | 18                      | 80                      | 77                      |



INTRA-ARTICULAR INJECTION (IAI) (RULES 3313-14, 4221) VIOLATIONS

TOTAL ECM NOTICES FILED

TOTAL ECM CHARGES FILED

Admissions: 6
HIWU/Internal Adjudication
Panel (IAP) Decisions: 1
Withdrawn Charges: 2
Stayed: 0

92.2%

of notices filed resulted in Charges

IAI Cases not included



### Filed Notices by Rule Violation with Percentages

| Total Notices Filed       | 103 |                |
|---------------------------|-----|----------------|
| Total EAD Notices Filed   |     |                |
| Presence (Rule 3212)      | 19  | 22.3%<br>82.6% |
| Possession (Rule 3214(a)) | 4   | 17.4%          |

| Total ECM Notices Filed     | 80 | 77.7% |
|-----------------------------|----|-------|
| Presence (Rule 3312)        | 73 | 91.3% |
| ECM Method (Rule 3313)/TCO2 | 6  | 7.5%  |
| Other Violations            | 1  | 1.2%  |

#### Notice:

A Notice served by HIWU is the first communication with the Responsible Person; it sets forth the facts with respect to a possible violation of the ADMC Program and requests an explanation from the Responsible Person.

### Filed Charges by Rule Violation with Percentages

| Total Charges Filed         | 95 |       |
|-----------------------------|----|-------|
|                             |    |       |
| Total EAD Charges Filed     | 18 | 18.9% |
| Presence (Rule 3212)        | 15 | 83.3% |
| Possession (Rule 3214(a))   | 3  | 16.7% |
|                             |    |       |
|                             |    |       |
| Total ECM Charges Filed     | 77 | 81.1% |
| Presence (Rule 3312)        | 73 | 94.8% |
| ECM Method (Rule 3313)/TCO2 | 3  | 3.9%  |
| Other Violations            | 1  | 1.3%  |

#### Charge:

A Charge is served by HIWU when it has made the determination that it is moving forward with a case against a Responsible Person; it is not served until after HIWU has received and reviewed the explanation and any other information submitted by the Responsible Person (if they have done so).

#### **RESULTS OF CHARGES FILED\***

|                                 | Anti-Doping |        | Controlled Medication |        |  |
|---------------------------------|-------------|--------|-----------------------|--------|--|
|                                 | Total       | %      | Total                 | %      |  |
| Admission                       | 0           | 0.0%   | 38                    | 49.4%  |  |
| Arbitral Body/IAP/HIWU Decision | 0           | 0.0%   | 23                    | 29.9%  |  |
| Withdrawal                      | 0           | 0.0%   | 1                     | 1.3%   |  |
| Stayed                          | 7           | 38.9%  | 11                    | 14.3%  |  |
| Pending                         | 11          | 61.1%  | 4                     | 5.1%   |  |
| Total                           | 18          | 100.0% | 77                    | 100.0% |  |

<sup>\*</sup> This information is up to date through September 23, 2024.